Caladrius Biosciences, Inc. Aktie News

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA”

All Merger-related proposals approved at the Annual Meeting of Stockholders All Merger-related proposals approved at the Annual Meeting of Stockholders

Study to be part of Roche's Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations

Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO Kristen Buck - EVP, Research and Development & CMO James Nisco - VP, Finance & Treasury Conference Call Participants Kumar Raja - Brookline Capital Pete Enderlin - MAZ Partners Operator Welcome to...

Top-line data from all subjects expected by the first quarter of 2023 Top-line data from all subjects expected by the first quarter of 2023

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, announces that its merger partner in the creation of Lisata Therapeutics (“Lisata”), Cend Therapeutics, Inc. (“Cend”) today indicated...

Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at t...